邦顺制药由79岁董事长李邦良控股31%，60年代火箭制造专业高材生

Core Viewpoint - Hangzhou Bangshun Pharmaceutical Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, focusing on developing differentiated oral small molecule drugs for oncology and autoimmune diseases, with a strong emphasis on unmet clinical needs in these areas [2][3]. Company Overview - Bangshun Pharmaceutical was established in May 2020 and is nearing commercialization, specializing in oncology and autoimmune diseases [2]. - The company has developed a pipeline that includes one drug candidate in the New Drug Application (NDA) stage (Bezeixin), one candidate in the registration clinical stage (CX1440), and five candidates in the preclinical stage (CX03, CX12, CX13, CX15, and CX16) [3]. Financial Performance - The company reported revenues of RMB 943,000 in 2024, with no revenue in the first nine months of 2025 [4]. - The total losses for the periods were RMB 88.44 million in 2024 and RMB 66.34 million in the first nine months of 2025 [4]. - Research and development costs were RMB 64.53 million in 2024 and RMB 50.98 million in the first nine months of 2025 [4]. Leadership - The board of directors includes four members, with Li Bangliang serving as the chairman and executive director, bringing over 50 years of experience in the pharmaceutical industry [6]. - Li Yuedong, the executive director and deputy general manager, has over 30 years of experience in the pharmaceutical sector, focusing on commercialization and regulatory affairs [8][9].